ClinicalTrials.gg
TerminatedNCT02457598Updated Jun 17, 2025Results posted

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

A Phase 1 interventional study of Tirabrutinib and Idelalisib in B-cell Malignancies, sponsored by Gilead Sciences. Terminated at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Why this study was terminated
The goal of the study was to improve tolerability while maintaining or increasing efficacy. The results of this study showed no efficacy advantage although the combinations were well tolerated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
203
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO/GS-4059) in combination with other targeted anti-cancer therapies and to evaluate the long-term safety of tirabrutinib as a monotherapy and in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies.

This study consists of three parts: Dose Escalation, Dose Expansion, and Long-term Safety Monitoring. During the Dose Escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib +/- obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety, tolerability, PK, and pharmacodynamics. The Long-term Safety Monitoring phase will evaluate the long-term safety of tirabrutinib both as a monotherapy and in combination with other anti-cancer therapies. As of Amendment 9, all participants currently on the study who have no clinical evidence of disease progression will transition into long-term safety monitoring. Participants from the ongoing Study GS-US-401-1787 and participants who came off Study GS-US-401-1757 and Study GS-US-401-1787 but continued to receive treatment via named patient use (or individual expanded use) will be enrolled into the long-term safety monitoring group (Group VI). Participants enrolled in Group VI will continue the same treatment regimen in Study GS-US-401-1787 or named patient use (or individual expanded use). As of Protocol Amendment 8, the maximum treatment duration for any participant is an additional 6 years from the date of this amendment (ie. until November 2025). As of Amendment 9, entospletinib will be provided until 31 December 2020 to participants who are currently receiving entospletinib. Participants treated with entospletinib as part of a combination regimen with tirabrutinib will stop receiving entospletinib by 31 December 2020 but may continue to be treated with tirabrutinib monotherapy. Idelalisib will be provided as 50 mg tablets until 31 December 2020 and 100 mg tablets until study completion. Participants assigned to the 50 mg tablet will be given the option, at the investigator's discretion, to switch to 100 mg once daily idelalisib dose.

02

Conditions studied

  • B-cell Malignancies
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL) (meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria 2008), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), or non-germinal center B-cell lymphoma (GCB) diffuse large B-cell lymphoma (DLBCL) as documented by medical records on World Health Organization (WHO) criteria
  • Prior treatment for FL, MZL, SLL, MCL, WM with ≥ 2 or for CLL or non-GCB DLBCL ≥ 1 chemotherapy-based or immunotherapy-based regimen, and not transplant eligible and have had either progressive disease (PD) or no response to previous treatment
  • For diseases other than Waldenstrom's macroglobulinemia (WM), presence of radiographically measurable presence of ≥ 1 lesion that measures ≥ 2.0 cm in the longest dimension (LD) and ≥ 1.0 cm in the longest perpendicular dimension (LPD)
  • (ECOG) ≤ 2
  • ≥ 50 x 10\^9/L; ≥ 8.0 g/dL; (ANC) ≥ 1.0 x 10\^9/L
  • Without transfusion and growth factors within 7 days
  • /alanine transaminase (AST/ALT) ≤ 2.5 x (ULN)
  • Total ≤ 1.5 x ULN
  • Creatinine ≤ 1.5 x ULN or (CrCl) ≥ 60 mL/min
  • Not pregnant
  • Willingness and ability to comply with protocol-specified Pneumocystis jirovecii pneumonia (PJP) prophylaxis
  • Long-term Safety Monitoring group only (Group VI):

    • Currently enrolled in Study GS-US-401-1787 or previously enrolled in Study GS-US-401-1757 or Study GS-US-401-1787 and currently receiving continued treatment via named patient use
    • Continuing to benefit from the current treatment regimen in the opinion of the investigator/treating physician

Key Exclusion Criteria:

  • surface antigen (HBsAG) positive or hepatitis B core antibody positive
  • virus (HCV) antibody positive
  • History of long syndrome or whose corrected QT(QTc) interval measured (Fridericia method) at screening is prolonged (>450 ms)
  • Long-term Safety Monitoring group only (Group VI):

    • Evidence of clinical or radiological disease progression

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)

    Participants will receive tirabrutinib 20 mg tablet once daily (QD) for up to 209 weeks and idelalisib 50 mg tablet twice daily (BID) orally for up to 120 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Idelalisib

  • Experimental
    Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)

    Participants will receive tirabrutinib 40 mg tablet QD for up to 251 weeks and idelalisib 50 mg tablet BID orally, for up to 245 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Idelalisib

  • Experimental
    Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)

    Participants will receive tirabrutinib 80 mg tablet QD for up to 212 weeks and idelalisib 50 mg tablet BID orally, for up to 26 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Idelalisib

  • Experimental
    Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)

    Participants will receive tirabrutinib 80 mg tablet QD for up to 227 weeks and idelalisib 100 mg tablet QD orally, for up to 227 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Idelalisib

  • Experimental
    Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)

    Participants will receive tirabrutinib 160 mg tablet QD for up to 151 weeks and idelalisib 100 mg tablet QD orally, for up to 151 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Idelalisib

  • Experimental
    Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)

    Participants will receive tirabrutinib 20 mg tablet BID for up to 207 weeks and idelalisib 50 mg tablet BID orally, for up to 207 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Idelalisib

  • Experimental
    Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)

    Participants will receive tirabrutinib 40 mg tablet QD for up to 250 weeks and entospletinib 200 mg tablet QD orally, for up to 250 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Entospletinib

  • Experimental
    Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)

    Participants will receive tirabrutinib 80 mg tablet QD for up to 234 weeks and entospletinib 200 mg tablet QD orally, for up to 220 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Entospletinib

  • Experimental
    Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)

    Participants will receive tirabrutinib 150 mg tablet QD for up to 103 weeks and entospletinib 200 mg tablet QD orally, for up to 88 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Entospletinib

  • Experimental
    Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)

    Participants will receive tirabrutinib 40 mg tablet QD for up to 119 weeks and entospletinib 400 mg tablet QD orally, for up to 119 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Entospletinib

  • Experimental
    Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)

    Participants will receive tirabrutinib 80 mg tablet QD for up to 232 weeks and entospletinib 400 mg tablet QD orally, for up to 229 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Entospletinib

  • Experimental
    Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)

    Participants will receive tirabrutinib 160 mg tablet QD for up to 44 weeks and entospletinib 400 mg tablet QD orally, for up to 44 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Entospletinib

  • Experimental
    Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ obinutuzumab 1000 mg)

    Participants will receive tirabrutinib 80 mg tablet QD for up to 199 weeks; Idelalisib 100 mg tablet QD orally for up to 199 weeks, and single dose of obinutuzumab 1000 mg intravenously (IV) for up to 22 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Idelalisib · Drug: Obinutuzumab

  • Experimental
    Combination IV (Tirabrutinib 80 mg QD+ entospletinib 400 mg QD+ obinutuzumab 1000 mg)

    Participants will receive tirabrutinib 80 mg tablet QD for up to 196 weeks; entospletinib 400 mg tablet QD orally for up to 196 weeks and single dose of obinutuzumab 1000 mg IV for up to 22 weeks. Both drugs will be administered for 28-day cycles.

    Drug: Tirabrutinib · Drug: Entospletinib · Drug: Obinutuzumab

  • Experimental
    Group V Single Agent Tirabrutinib

    Participants will receive tirabrutinib 80 mg tablet QD orally, for each 28-day cycle up to 194 weeks.

    Drug: Tirabrutinib

  • Experimental
    Group VI Single Agent Tirabrutinib: CLL

    Participants with CLL who received tirabrutinib in this or a previous tirabrutinib study will continue to receive tirabrutinib at the original dose (between the range of 40 - 400 mg), tablet QD, for each 28-day cycle up to 441 weeks. Participants will be monitored for the long-term safety of tirabrutinib in this group.

    Drug: Tirabrutinib

  • Experimental
    Group VI Single Agent Tirabrutinib: NHL

    Participants with NHL who received tirabrutinib in this or a previous tirabrutinib study will continue to receive tirabrutinib at the original dose (between the range of 60 - 480 mg), tablet QD, for each 28-day cycle up to 441 weeks. Participants will be monitored for the long-term safety of tirabrutinib in this group.

    Drug: Tirabrutinib

Interventions

  • Capsules or tablets administered orally

    Also known as: ONO/GS-4059

  • Tablets administered orally twice daily

    Also known as: Zydelig®, GS-1101, CAL-101

  • Tablets administered orally

    Also known as: GS-9973

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose Limiting Toxicities (DLTs)

    A DLT was defined as a ≥ Grade 3 AE that was assessed as related to study drug that occurred during the 28-day DLT assessment period with protocol-defined allowed exceptions. Any treatment-emergent adverse event (TEAE) that was, in the opinion of the Clinical Trial Steering Committee, of potential clinical significance such that further dosing exposed participants to unacceptable risk, was considered a DLT.

    Time frame: Up to 28 days

  2. Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) at Week 12 in Participants With Non-Chronic Lymphocytic Leukemia (CLL) Type NHL

    ORR for Waldenstrom Macroglobulinemia(WM):CR+VGPR+PR+MPR. CR: Absence of serum monoclonal IgM protein; normal serum IgM level: complete resolution of extramedullary disease, morphologically normal bone marrow/aspirate and trephine biopsy. Very good partial response (VGPR):Detectable monoclonal IgM; ≥90% reduction in serum IgM; Complete resolution of extramedullary disease; No new signs/symptoms. PR: Monoclonal immunoglobulin M (IgM) protein is detectable ≥50% but \<90% reduction in serum IgM level from baseline; reduction of extramedullary disease; no new signs or symptoms of active disease. Minor response (MPR):Detectable monoclonal IgM; ≥25% but \<50% reduction in serum IgM; No progression of extramedullary disease; No new signs/symptoms. Clopper-Pearson method was used in analysis. Data is reported by disease type: WM; Follicular Lymphoma (FL);Mantle Cell Lymphoma (MCL);Small Lymphocytic Lymphoma (SLL);Marginal Zone Lymphoma (MZL);Diffuse Large B-Cell Lymphoma (DLBCL) as applicable.

    Time frame: Week 12

  3. ORR: Percentage of Participants With CR or PR in Participants With CLL at Week 24

    ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR). CR and PR are defined in outcome measure#2. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded off.

    Time frame: Week 24

  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. TEAEs were defined as an AE that onset in the period from the first dose of study treatment to 30 days after the last dose of study treatment. Percentages were rounded off.

    Time frame: First dose up to last dose date (up to 441 weeks) plus 30 days

Secondary outcomes

  1. ORR: Percentage of Participants With Complete Response (CR) or Partial Response (PR) in the Dose Escalation and Expansion Phase

    ORR for WM is CR + VGPR + PR + MPR. CR, PR, VGPR and MPR are defined in outcome measure#2. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded off. Data is reported by disease type: CLL ; FL; MCL; MZL; SLL; WM; DLBCL.

    Time frame: Up to 281 weeks

  2. Progression Free Survival (PFS) During the Dose Escalation Phase and Dose Expansion Phase

    PFS was defined as the interval from the start of the study therapy to the earlier of the first documentation of definite disease progression (PD) or death from any cause. PD: ≥ 25% increase in serum IgM level from lowest nadir (requires confirmation) and/or progression in clinical features attributable to the disease. Kaplan-Meier (KM) estimate were used in outcome measure analysis. Data is reported by disease type: CLL; FL; MCL; MZL; other NHL; DLBCL.

    Time frame: Up to 281 weeks

  3. Duration of Response (DOR) During the Dose Escalation Phase and Dose Expansion Phase

    DOR was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of definite disease progression or death from any cause. CR and PR are defined in outcome measure# 2. PD is defined in outcome measure #6. KM estimates were used in outcome measure analysis. Data is reported by disease type: CLL; FL; MCL; MZL; SLL; WM; DLBCL

    Time frame: Up to 281 weeks

  4. Time to Response (TTR) During the Dose Escalation Phase and Dose Expansion Phase

    TTR was defined as the interval from start of treatment to the first documentation of CR or PR. CR and PR are defined in outcome measure# 2. Data is reported by disease type: CLL; FL; MCL; MZL; SLL; WM; DLBCL.

    Time frame: Up to 281 weeks

  5. Percentage of Participants Who Achieved Minimal Residual Negative Disease (< 1 Leukemia Cell/10,000 Leukocytes) During the Dose Escalation Phase and Dose Expansion Phase in Participants With CLL

    Achieving Minimal Residual Disease was defined as \< 1 leukemia cell/10,000 leukocytes (10-4) in participants who have also achieved a CR. CR is defined in outcome measure #2.

    Time frame: Up to 281 weeks

  6. Pharmacokinetic (PK) Parameter: AUCtau of Tirabrutinib 80 mg

    AUCtau was defined as concentration of drug over time. Area under the concentration verses time curve over the dosing interval (AUctau). The data for AUCtau is reported for tirabrutinib 80 mg as monotherapy and in combination with idelalisib 50 mg and 100 mg and entospletinib 200 mg and 400 mg.

    Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose

  7. PK Parameter: Cmax of Tirabrutinib 80 mg

    Cmax was defined as the maximum observed concentration of drug. The data for Cmax is reported for tirabrutinib 80 mg as monotherapy and in combination with idelalisib 50 mg and 100 mg and entospletinib 200 mg and 400 mg.

    Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose

  8. PK Parameter: AUCtau of Idelalisib When Given in Combination With Tirabrutinib

    AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose

  9. PK Parameter: Cmax of Idelalisib When Given in Combination With Tirabrutinib

    Cmax was defined as the maximum observed concentration of drug.

    Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose

  10. PK Parameter: AUCtau of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib

    AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose

  11. PK Parameter: Cmax of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib

    Cmax was defined as the maximum observed concentration of drug.

    Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose

  12. PK Parameter: AUCtau of Entospletinib When Given in Combination With Tirabrutinib

    AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose

  13. PK Parameter: Cmax of Entospletinib When Given in Combination With Tirabrutinib

    Cmax was defined as the maximum observed concentration of drug.

    Time frame: Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose

07

Results

Posted Jun 17, 2025

Participant flow

Participants were enrolled at study sites in France, the United Kingdom and the United States.

Participant flow — Overall Study
MilestoneCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mgGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHL
Started38425953633788672933
Rollover participants10000000000000000
Completed10000100000000000
Not completed28425943633788672933
Withdrew: Progressive disease22111732112456221011
Withdrew: Investigator's discretion022200012010221500
Withdrew: Study terminated by sponsor01041010004010810
Withdrew: Adverse event01141001016001200
Withdrew: Death00030100003001201
Withdrew: Transition to the mhra's special scheme02010001004000111
Withdrew: Withdrew consent00000002003001000
Withdrew: Unacceptable toxicity00000000001011100
Withdrew: Intercurrent illness00000000001000000
Withdrew: Protocol violation00000000001000000

Outcome measures

PrimaryPercentage of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as a ≥ Grade 3 AE that was assessed as related to study drug that occurred during the 28-day DLT assessment period with protocol-defined allowed exceptions. Any treatment-emergent adverse event (TEAE) that was, in the opinion of the Clinical Trial Steering Committee, of potential clinical significance such that further dosing exposed participants to unacceptable risk, was considered a DLT.

Time frame:
Up to 28 days
Reported as:
Number · percentage of participants
Percentage of Participants With Dose Limiting Toxicities (DLTs)
percentage of participantsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)
Percentage of Participants With Dose Limiting Toxicities (DLTs)000002000000000
PrimaryObjective Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) at Week 12 in Participants With Non-Chronic Lymphocytic Leukemia (CLL) Type NHL

ORR for Waldenstrom Macroglobulinemia(WM):CR+VGPR+PR+MPR. CR: Absence of serum monoclonal IgM protein; normal serum IgM level: complete resolution of extramedullary disease, morphologically normal bone marrow/aspirate and trephine biopsy. Very good partial response (VGPR):Detectable monoclonal IgM; ≥90% reduction in serum IgM; Complete resolution of extramedullary disease; No new signs/symptoms. PR: Monoclonal immunoglobulin M (IgM) protein is detectable ≥50% but \<90% reduction in serum IgM level from baseline; reduction of extramedullary disease; no new signs or symptoms of active disease. Minor response (MPR):Detectable monoclonal IgM; ≥25% but \<50% reduction in serum IgM; No progression of extramedullary disease; No new signs/symptoms. Clopper-Pearson method was used in analysis. Data is reported by disease type: WM; Follicular Lymphoma (FL);Mantle Cell Lymphoma (MCL);Small Lymphocytic Lymphoma (SLL);Marginal Zone Lymphoma (MZL);Diffuse Large B-Cell Lymphoma (DLBCL) as applicable.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) at Week 12 in Participants With Non-Chronic Lymphocytic Leukemia (CLL) Type NHL
percentage of participantsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mg
Disease Subtype: FL—0 (0 to 84.2)0 (0 to 97.5)20.0 (0.5 to 71.6)—0 (0 to 84.2)—50.0 (1.3 to 98.7)100.0 (2.5 to 100.0)0 (0 to 97.5)18.2 (5.2 to 40.3)—25.0 (0.6 to 80.6)40.0 (5.3 to 85.3)—
Disease Subtype: MCL—0 (0 to 97.5)————0 (0 to 97.5)———60.0 (26.2 to 87.8)—100.0 (2.5 to 100.0)——
Disease Subtype: SLL50.0 (1.3 to 98.7)—————0 (0 to 84.2)————————
Disease Subtype: MZL——100.0 (2.5 to 100.0)33.3 (0.8 to 90.6)—0 (0 to 97.5)———0 (0 to 97.5)50.0 (6.8 to 93.2)—100.0 (2.5 to 100)50.0 (1.3 to 98.7)—
Disease Subtype: WM———100.0 (39.8 to 100.0)—0 (0 to 97.5)———0 (0 to 97.5)42.9 (9.9 to 81.6)————
Disease Subtype: DLBCL——0 (0 to 97.5)14.3 (0.4 to 57.9)22.2 (2.8 to 60.0)——0 (0 to 97.5)100.0 (15.8 to 100.0)—17.9 (6.1 to 36.9)12.5 (0.3 to 52.7)———
PrimaryORR: Percentage of Participants With CR or PR in Participants With CLL at Week 24

ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR). CR and PR are defined in outcome measure#2. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded off.

Time frame:
Week 24
Reported as:
Number · percentage of participants
ORR: Percentage of Participants With CR or PR in Participants With CLL at Week 24
percentage of participantsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mg
ORR: Percentage of Participants With CR or PR in Participants With CLL at Week 24100.0 (2.5 to 100)80.0 (28.4 to 99.5)100.0 (2.5 to 100)66.7 (22.3 to 95.7)—100.0 (2.5 to 100)—66.7 (9.4 to 99.2)——28.6 (3.7 to 71)———79.3 (60.3 to 92)
PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. TEAEs were defined as an AE that onset in the period from the first dose of study treatment to 30 days after the last dose of study treatment. Percentages were rounded off.

Time frame:
First dose up to last dose date (up to 441 weeks) plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mgGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHL
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)100.0100.0100.0100.0100.0100.0100.0100.0100.0100.096.275.0100.0100.0100.0100.0100.0
SecondaryORR: Percentage of Participants With Complete Response (CR) or Partial Response (PR) in the Dose Escalation and Expansion Phase

ORR for WM is CR + VGPR + PR + MPR. CR, PR, VGPR and MPR are defined in outcome measure#2. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded off. Data is reported by disease type: CLL ; FL; MCL; MZL; SLL; WM; DLBCL.

Time frame:
Up to 281 weeks
Reported as:
Number · percentage of participants
ORR: Percentage of Participants With Complete Response (CR) or Partial Response (PR) in the Dose Escalation and Expansion Phase
percentage of participantsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV (Tirabrutinib 80 mg QD+Entospletinib 400 mg QD+ Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mg
Disease Subtype: CLL100.0 (2.5 to 100.0)100.0 (47.8 to 100.0)100.0 (2.5 to 100.0)83.3 (35.9 to 99.6)—100.0 (2.5 to 100.0)—100.0 (29.2 to 100.0)——100.0 (59 to 100.0)———86.2 (68.3 to 96.1)
Disease Subtype: FL—0 (0 to 84.2)0 (0 to 97.5)20.0 (0.5 to 71.6)—50.0 (1.3 to 98.7)—50.0 (1.3 to 98.7)100.0 (2.5 to 100.0)100.0 (2.5 to 100.0)36.4 (17.2 to 59.3)—75.0 (19.4 to 99.4)60.0 (14.7 to 94.7)—
Disease Subtype: MCL—100.0 (2.5 to 100.0)————0 (0 to 97.5)———70.0 (34.8 to 93.3)—100.0 (2.5 to 100.0)——
Disease Subtype: MZL——100.0 (2.5 to 100.0)33.3 (0.8 to 90.6)—0 (0 to 97.5)———0 (0 to 97.5)50.0 (6.8 to 93.2)—100.0 (2.5 to 100.0)50.0 (1.3 to 98.7)—
Disease Subtype: SLL50.0 (1.3 to 98.7)—————100.0 (15.8 to 100.0)————————
Disease Subtype: WM———100.0 (39.8 to 100.0)—0 (0 to 97.5)———100.0 (2.5 to 100.0)85.7 (42.1 to 99.6)————
Disease Subtype: DLBCL——0 (0 to 97.5)14.3 (0.4 to 57.9)33.3 (7.5 to 70.1)——0 (0 to 97.5)100.0 (15.8 to 100.0)—25.0 (10.7 to 44.9)12.5 (0.3 to 52.7)———
SecondaryProgression Free Survival (PFS) During the Dose Escalation Phase and Dose Expansion Phase

PFS was defined as the interval from the start of the study therapy to the earlier of the first documentation of definite disease progression (PD) or death from any cause. PD: ≥ 25% increase in serum IgM level from lowest nadir (requires confirmation) and/or progression in clinical features attributable to the disease. Kaplan-Meier (KM) estimate were used in outcome measure analysis. Data is reported by disease type: CLL; FL; MCL; MZL; other NHL; DLBCL.

Time frame:
Up to 281 weeks
Reported as:
Median · months
Progression Free Survival (PFS) During the Dose Escalation Phase and Dose Expansion Phase
monthsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mg
Disease Subtype: CLLNA (NA to NA)NA (20.8 to NA)31.8 (NA to NA)NA (8.3 to NA)—39.6 (NA to NA)—NA (NA to NA)——NA (NA to NA)———NA (NA to NA)
Disease Subtype: DLBCL——1.4 (NA to NA)1.5 (1.1 to 5.0)2.5 (1.2 to 11.0)——1.2 (NA to NA)NA (NA to NA)—2.8 (1.5 to 5.3)2.3 (1.4 to 4.1)———
Disease Subtype: FL—8.2 (5.3 to 11.1)5.3 (NA to NA)5.6 (1.0 to NA)—12.3 (5.4 to 19.3)—NA (NA to NA)19.4 (NA to NA)19.4 (NA to NA)11.0 (5.1 to 21.9)————
Disease Subtype: MCL—21.6 (NA to NA)————5.4 (NA to NA)———27.6 (16.8 to NA)————
Disease Subtype: other NHL13.7 (5.5 to 21.9)—6.0 (NA to NA)NA (2.5 to NA)—2.6 (1.2 to 4.0)56.9 (NA to NA)——NA (6.6 to NA)NA (8.6 to NA)—NA (5.6 to NA)NA (5.4 to NA)—
SecondaryDuration of Response (DOR) During the Dose Escalation Phase and Dose Expansion Phase

DOR was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of definite disease progression or death from any cause. CR and PR are defined in outcome measure# 2. PD is defined in outcome measure #6. KM estimates were used in outcome measure analysis. Data is reported by disease type: CLL; FL; MCL; MZL; SLL; WM; DLBCL

Time frame:
Up to 281 weeks
Reported as:
Median · months
Duration of Response (DOR) During the Dose Escalation Phase and Dose Expansion Phase
monthsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mg
Disease Subtype: CLLNA (NA to NA)NA (15.2 to NA)26.5 (NA to NA)NA (NA to NA)—34.1 (NA to NA)—NA (NA to NA)——NA (NA to NA)———NA (NA to NA)
Disease Subtype: FL———3.0 (NA to NA)—13.8 (NA to NA)—NA (NA to NA)16.6 (NA to NA)6.3 (NA to NA)17.3 (2.3 to NA)—NA (NA to NA)NA (4.4 to NA)—
Disease Subtype: MCL—10.7 (NA to NA)————————24.9 (14.0 to NA)—2.8 (NA to NA)——
Disease Subtype: SLL19.3 (NA to NA)—————51.4 (NA to NA)————————
Disease Subtype: MZL——3.3 (NA to NA)2.5 (NA to NA)——————NA (NA to NA)—8.2 (NA to NA)NA (NA to NA)—
Disease Subtype: WM———NA (20.1 to NA)—————NA (NA to NA)NA (13.9 to NA)————
Disease Subtype: DLBCL———3.9 (NA to NA)NA (6.4 to NA)———NA (NA to NA)—8.3 (1.4 to 23.5)NA (NA to NA)———
SecondaryTime to Response (TTR) During the Dose Escalation Phase and Dose Expansion Phase

TTR was defined as the interval from start of treatment to the first documentation of CR or PR. CR and PR are defined in outcome measure# 2. Data is reported by disease type: CLL; FL; MCL; MZL; SLL; WM; DLBCL.

Time frame:
Up to 281 weeks
Reported as:
Median · months
Time to Response (TTR) During the Dose Escalation Phase and Dose Expansion Phase
monthsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mg
Disease Subtype: CLL2.7 (2.7 to 2.7)5.6 (5.4 to 5.8)5.4 (5.4 to 5.4)5.6 (4.6 to 8.0)—5.6 (5.6 to 5.6)—5.4 (4.4 to 5.9)——5.9 (5.4 to 6.8)———5.5 (2.7 to 5.9)
Disease Subtype: FL———2.6 (2.6 to 2.6)—5.5 (5.5 to 5.5)—2.8 (2.8 to 2.8)2.8 (2.8 to 2.8)13.0 (13.0 to 13.0)3.7 (2.8 to 11.0)—3.9 (2.6 to 9.2)2.9 (2.6 to 4.6)—
Disease Subtype: MCL—10.8 (10.8 to 10.8)————————2.8 (2.8 to 8.4)—2.8 (2.8 to 2.8)——
Disease Subtype: SLL2.7 (2.7 to 2.7)—————5.5 (5.4 to 5.6)————————
Disease Subtype: MZL——2.8 (2.8 to 2.8)2.9 (2.9 to 2.9)——————2.7 (2.7 to 2.8)—2.7 (2.7 to 2.7)2.8 (2.8 to 2.8)—
Disease Subtype: WM———2.8 (2.6 to 3.0)—————17.5 (17.5 to 17.5)4.1 (2.8 to 9.1)————
Disease Subtype: DLBCL———1.6 (1.6 to 1.6)1.8 (1.4 to 4.6)———1.9 (1.1 to 2.8)—1.5 (1.3 to 13.0)1.6 (1.6 to 1.6)———
SecondaryPercentage of Participants Who Achieved Minimal Residual Negative Disease (< 1 Leukemia Cell/10,000 Leukocytes) During the Dose Escalation Phase and Dose Expansion Phase in Participants With CLL

Achieving Minimal Residual Disease was defined as \< 1 leukemia cell/10,000 leukocytes (10-4) in participants who have also achieved a CR. CR is defined in outcome measure #2.

Time frame:
Up to 281 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Residual Negative Disease (< 1 Leukemia Cell/10,000 Leukocytes) During the Dose Escalation Phase and Dose Expansion Phase in Participants With CLL
percentage of participantsCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mg
Percentage of Participants Who Achieved Minimal Residual Negative Disease (< 1 Leukemia Cell/10,000 Leukocytes) During the Dose Escalation Phase and Dose Expansion Phase in Participants With CLL040016.7—0—0——28.6———20.7
SecondaryPharmacokinetic (PK) Parameter: AUCtau of Tirabrutinib 80 mg

AUCtau was defined as concentration of drug over time. Area under the concentration verses time curve over the dosing interval (AUctau). The data for AUCtau is reported for tirabrutinib 80 mg as monotherapy and in combination with idelalisib 50 mg and 100 mg and entospletinib 200 mg and 400 mg.

Time frame:
Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Reported as:
Mean · ng*h/mL
Pharmacokinetic (PK) Parameter: AUCtau of Tirabrutinib 80 mg
ng*h/mLCombination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Group V Single Agent Tirabrutinib
Pharmacokinetic (PK) Parameter: AUCtau of Tirabrutinib 80 mg984.0 ± 342.181205.6 ± 245.891794.1 ± 181.151251.6 ± 387.461088.8 ± 545.52
SecondaryPK Parameter: Cmax of Tirabrutinib 80 mg

Cmax was defined as the maximum observed concentration of drug. The data for Cmax is reported for tirabrutinib 80 mg as monotherapy and in combination with idelalisib 50 mg and 100 mg and entospletinib 200 mg and 400 mg.

Time frame:
Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Tirabrutinib 80 mg
ng/mLCombination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Group V Single Agent Tirabrutinib
PK Parameter: Cmax of Tirabrutinib 80 mg192.3 ± 58.21219.5 ± 12.02304.7 ± 34.67246.3 ± 11.37215.2 ± 66.10
SecondaryPK Parameter: AUCtau of Idelalisib When Given in Combination With Tirabrutinib

AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Reported as:
Mean · h*ng/mL
PK Parameter: AUCtau of Idelalisib When Given in Combination With Tirabrutinib
h*ng/mLCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)
PK Parameter: AUCtau of Idelalisib When Given in Combination With Tirabrutinib6620.6 ± 661.195433.2 ± 1287.956735.0 ± 1859.799488.0 ± 3263.4419305.4 ± 5616.537093.0 ± 4025.04
SecondaryPK Parameter: Cmax of Idelalisib When Given in Combination With Tirabrutinib

Cmax was defined as the maximum observed concentration of drug.

Time frame:
Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Idelalisib When Given in Combination With Tirabrutinib
ng/mLCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)
PK Parameter: Cmax of Idelalisib When Given in Combination With Tirabrutinib1920.0 ± 252.391893.3 ± 750.821324.8 ± 389.651790.0 ± 268.703325.0 ± 481.281844.0 ± 518.58
SecondaryPK Parameter: AUCtau of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib

AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Reported as:
Mean · h*ng/mL
PK Parameter: AUCtau of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib
h*ng/mLCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)
PK Parameter: AUCtau of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib19922.6 ± 9354.4722519.6 ± 8233.7741327.5 ± 20049.4449192.7 ± 15719.5236824.3 ± 9670.67225371.5 ± 22931.89
SecondaryPK Parameter: Cmax of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib

Cmax was defined as the maximum observed concentration of drug.

Time frame:
Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib
ng/mLCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)
PK Parameter: Cmax of Metabolite of Idelalisib (GS-563117) When Given in Combination With Tirabrutinib2723.3 ± 1045.102760.0 ± 1105.312542.5 ± 1820.543415.0 ± 360.622592.5 ± 503.483682.0 ± 1950.35
SecondaryPK Parameter: AUCtau of Entospletinib When Given in Combination With Tirabrutinib

AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Reported as:
Mean · h*ng/mL
PK Parameter: AUCtau of Entospletinib When Given in Combination With Tirabrutinib
h*ng/mLCombination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)
PK Parameter: AUCtau of Entospletinib When Given in Combination With Tirabrutinib7738.7 ± 1793.684266.2 ± 1574.309968.3 ± 295.6914027.8 ± 6979.1812959.9 ± 2250.666196.8 ± 1018.98
SecondaryPK Parameter: Cmax of Entospletinib When Given in Combination With Tirabrutinib

Cmax was defined as the maximum observed concentration of drug.

Time frame:
Cycle 1 Day 8: Predose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Entospletinib When Given in Combination With Tirabrutinib
ng/mLCombination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)
PK Parameter: Cmax of Entospletinib When Given in Combination With Tirabrutinib876.0 ± 367.98707.7 ± 397.04697.0 ± 313.931498.7 ± 619.571330.7 ± 382.0861.0 ± 276.17

Adverse events

Collected over Up to 441 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)0/3 (0%)2/3 (66.7%)3/3 (100%)
Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)2/8 (25%)3/8 (37.5%)8/8 (100%)
Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)1/4 (25%)2/4 (50%)4/4 (100%)
Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)6/25 (24%)13/25 (52%)24/25 (96%)
Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)1/9 (11.1%)2/9 (22.2%)9/9 (100%)
Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)2/5 (40%)4/5 (80%)5/5 (100%)
Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)0/3 (0%)3/3 (100%)3/3 (100%)
Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)0/6 (0%)4/6 (66.7%)6/6 (100%)
Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)0/3 (0%)1/3 (33.3%)3/3 (100%)
Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)0/3 (0%)1/3 (33.3%)3/3 (100%)
Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)8/78 (10.3%)36/78 (46.2%)73/78 (93.6%)
Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)2/8 (25%)2/8 (25%)5/8 (62.5%)
Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)1/6 (16.7%)4/6 (66.7%)6/6 (100%)
Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)1/7 (14.3%)7/7 (100%)7/7 (100%)
Group V Single Agent Tirabrutinib 80 mg3/29 (10.3%)10/29 (34.5%)29/29 (100%)
Group VI Single Agent Tirabrutinib: CLL0/3 (0%)1/3 (33.3%)3/3 (100%)
Group VI Single Agent Tirabrutinib: NHL1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 120
Most frequent serious events
EventCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mgGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHL
Febrile neutropeniaBlood and lymphatic system disorders1/30/80/41/250/90/50/30/60/30/30/780/80/60/70/291/30/3
Atrial fibrillationCardiac disorders0/30/80/40/250/90/51/31/60/30/31/780/80/60/70/290/30/3
DiarrhoeaGastrointestinal disorders1/30/80/40/250/90/50/30/60/30/30/780/80/60/70/290/30/3
Clostridium difficile colitisInfections and infestations0/30/80/40/250/90/50/30/61/30/30/780/80/60/70/290/30/3
DiverticulitisInfections and infestations1/30/80/40/250/90/50/30/60/30/30/780/80/60/70/290/30/3
PneumoniaInfections and infestations0/30/81/43/250/91/51/30/60/30/32/780/81/61/72/290/30/3
Streptococcal infectionInfections and infestations0/30/80/40/250/90/50/30/61/30/30/780/80/60/70/290/30/3
Upper respiratory tract infectionInfections and infestations0/30/80/40/250/90/50/31/60/30/32/780/80/60/70/290/31/3
Diabetes mellitusMetabolism and nutrition disorders0/30/80/40/250/90/51/30/60/30/30/780/80/60/70/290/30/3
Type 2 diabetes mellitusMetabolism and nutrition disorders0/30/80/40/250/90/50/30/61/30/30/780/80/60/70/290/30/3
Most frequent other events
Showing 10 of 327
Most frequent other events
EventCombination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV(Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent Tirabrutinib 80 mgGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHL
PyrexiaGeneral disorders3/32/81/43/251/91/50/32/60/31/314/780/81/61/73/290/30/3
ContusionInjury, poisoning and procedural complications3/32/80/44/250/91/50/32/60/31/315/780/80/60/76/290/30/3
ConstipationGastrointestinal disorders0/32/81/43/251/94/50/32/60/31/311/780/82/63/78/290/30/3
NauseaGastrointestinal disorders2/32/81/43/251/92/50/31/60/30/318/781/82/61/710/290/30/3
StomatitisGastrointestinal disorders2/31/80/43/250/90/51/30/60/30/30/780/82/60/70/290/30/3
FatigueGeneral disorders0/31/81/43/251/92/51/34/62/30/321/780/81/61/78/291/30/3
Oedema peripheralGeneral disorders2/30/81/43/251/91/51/30/60/31/32/780/80/61/76/290/30/3
ConjunctivitisInfections and infestations2/30/80/41/251/91/50/30/60/30/32/780/80/60/70/290/30/3
Herpes zosterInfections and infestations1/31/80/40/250/90/52/31/60/30/30/780/81/61/71/290/30/3
Lower respiratory tract infectionInfections and infestations1/31/81/41/250/90/50/31/61/30/36/780/80/60/75/292/30/3

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent TirabrutinibGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHLTotal
<=18 years000000000000000000
Between 18 and 65 years232122401102643381072
>=65 years15213713523524342123131
Age, Continuous
Age, Continuous(years)Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent TirabrutinibGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHLTotal
Mean66 ± 4.465 ± 9.762 ± 12.064 ± 13.273 ± 8.955 ± 12.870 ± 7.066 ± 11.167 ± 5.167 ± 1.268 ± 11.763 ± 11.959 ± 11.864 ± 14.470 ± 9.466 ± 4.074 ± 4.467 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent TirabrutinibGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHLTotal
Female3201042030225333121275
Male06415533331535341721128
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent TirabrutinibGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHLTotal
Hispanic or Latino000100000000000001
Not Hispanic or Latino38423743623517412323154
Unknown or Not Reported00012100102712661048
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent TirabrutinibGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHLTotal
American Indian or Alaska Native000000000000000000
Asian011200000020000006
Native Hawaiian or Other Pacific Islander000000000000000000
Black or African American000001000000000001
White37317333633465412133134
More than one race000000000000000000
Unknown or Not Reported00066100003032680062
Region of Enrollment
Region of Enrollment(Participants)Combination I (Tirabrutinib 20 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 40 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 50 mg BID)Combination I (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 160 mg QD+ Idelalisib 100 mg QD)Combination I (Tirabrutinib 20 mg BID+ Idelalisib 50 mg BID)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 150 mg QD+ Entospletinib 200 mg QD)Combination II (Tirabrutinib 40 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD)Combination II (Tirabrutinib 160 mg QD+ Entospletinib 400 mg QD)Combination III (Tirabrutinib 80 mg QD+ Idelalisib 100 mg QD+ Obinutuzumab 1000 mg)Combination IV (Tirabrutinib 80 mg QD+ Entospletinib 400 mg QD+Obinutuzumab 1000 mg)Group V Single Agent TirabrutinibGroup VI Single Agent Tirabrutinib: CLLGroup VI Single Agent Tirabrutinib: NHLTotal
France02286110123574770083
United Kingdom0421322042135100122383
United States32041222008020101037
08

Study locations

15 sites
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Indiana University Health Goshen Center for Cancer Care
    Goshen, Indiana 46506, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • CHRU de Lille, Hopital Claude Huriez
    Lille, 59037, France
  • Hopital Saint Eloi
    Montpellier, 34295, France
  • Chu Haut Leveque
    Pessac, 33604, France
  • Centre Hospitalier de Lyon Sud
    Pierre Benite, 69310, France
  • Institut Universitaire du Cancer-Oncopole I.U.C.T-O
    Toulouse, 3110, France
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, CB20QQ, United Kingdom
  • Cardiff and Vale Health Board, Clinical Research Facility
    Cardiff, CF14 4XW, United Kingdom
  • Leeds Teaching Hosptials NHS Trust, Dept of Haematology
    Leeds, LS9 7TF, United Kingdom
  • University Hospitals of Leicester NHS Trust
    Leicester, LE1 5WW, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Plymouth Hospitals NHS Trust
    Plymouth, PL68DH, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, Karlin L, Dyer MJS, Mitra SS, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jurgensmeier JM, Fegan CD. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 Jun 15;26(12):2810-2818. doi: 10.1158/1078-0432.CCR-19-3504. Epub 2020 Mar 10. PubMed 32156743 ↗
  • Morschhauser F, Dyer MJS, Walter HS, Danilov AV, Ysebaert L, Hodson DJ, Fegan C, Rule SA, Radford J, Cartron G, Bouabdallah K, Davies AJ, Spurgeon S, Rajakumaraswamy N, Li B, Humeniuk R, Huang X, Bhargava P, Jurgensmeier JM, Salles G. Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia. 2021 Jul;35(7):2108-2113. doi: 10.1038/s41375-020-01108-x. Epub 2020 Dec 17. No abstract available. PubMed 33328591 ↗
  • Salles, G., Dyer, MJS,. Hodson, DJ., et-al. Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma. Blood 2018; 132 (Supplement 1): 5344.
  • Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5. PubMed 26542378 ↗
  • Walter HS, Salles GA, Dyer MJ. New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jun 2;374(22):2185-6. doi: 10.1056/NEJMc1602674. No abstract available. PubMed 27248633 ↗
  • Morschhauser, F., Radford, J., Ysebaert, L., et-al. Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma. Blood 2018; 132 (Supplement 1): 5345.
  • Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJS. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. Blood. 2017 May 18;129(20):2808-2810. doi: 10.1182/blood-2017-02-765115. Epub 2017 Apr 4. No abstract available. PubMed 28377400 ↗
  • Yahiaoui A, Meadows SA, Sorensen RA, Cui ZH, Keegan KS, Brockett R, Chen G, Queva C, Li L, Tannheimer SL. PI3Kdelta inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kdelta and BTK inhibitors. PLoS One. 2017 Feb 8;12(2):e0171221. doi: 10.1371/journal.pone.0171221. eCollection 2017. PubMed 28178345 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Sep 2024, 111 months.

Results were first posted in Jun 2025, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2015
First posted
May 29, 2015
StartActual
Jun 16, 2015
Primary completionActual
Sep 25, 2024
CompletionActual
Sep 25, 2024
Results first posted
Jun 17, 2025
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02457598
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 29, 2015
Start date
Jun 16, 2015
Primary completion
Sep 25, 2024
Completion
Sep 25, 2024
Results posted
Jun 17, 2025
Last update
Jun 17, 2025

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirabrutinib

Start the discussion